ω-3 多不饱和脂肪酸通过 AMPK/mTOR 通路对脓毒症的保护作用。
Protective effect of omega-3 polyunsaturated fatty acids on sepsis via the AMPK/mTOR pathway.
机构信息
Wuhan Fourth Hospital, Wuhan, China.
Emergency Center, Zhongnan Hospital of Wuhan University, Wuhan, China.
出版信息
Pharm Biol. 2023 Dec;61(1):306-315. doi: 10.1080/13880209.2023.2168018.
CONTEXT
Sepsis is a systemic inflammatory response caused by infection, with high morbidity and mortality. Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) have reported biological activities.
OBJECTIVE
This study explored the signaling pathways through which ω-3 PUFAs protect against sepsis-induced multiorgan failure.
MATERIALS AND METHODS
Septic Sprague-Dawley (SD) rat model was established by the cecum ligation perforation (CLP) method. Rats were divided into control, sham, model, parenteral ω-3 PUFAs (0.5 g/kg) treatment, ω-3 PUFAs (0.5 g/kg) + AMPK inhibitor Compound C (30 mg/kg) treatment, and ω-3 PUFAs (0.5 g/kg) + mTOR activator MHY1485 (10 mg/kg) treatment groups. The serum inflammatory cytokines were measured using ELISA. Organ damage-related markers cTnI, CK, CK-MB, Cr, BUN, ALT, and AST were measured using an automated chemical analyzer. The AMPK/mTOR pathway in liver, kidney, and myocardial tissues was detected using western blot and qRT-PCR methods.
RESULTS
CLP treatment enhanced the secretion of pro-inflammatory cytokines and multi-organ related markers, along with increased p-AMPK/AMPK ratio (from 0.47 to 0.87) and decreased p-mTOR/mTOR ratio (from 0.33 to 0.12) in rats. The inflammation response and multi-organ injury induced by CLP treatment could be partially counteracted by 0.5 g/kg parenteral ω-3 PUFA treatment. The activated AMPK/mTOR pathway in CLP-induced rats was further promoted. Finally, Compound C and MHY1485 could reverse the effects of parenteral ω-3 PUFA treatment on sepsis rats.
DISCUSSION AND CONCLUSION
ω-3 PUFAs ameliorated sepsis development by activating the AMPK/mTOR pathway, serving as a potent therapeutic agent for sepsis. Further studies may validate potential clinical use.
背景
脓毒症是由感染引起的全身性炎症反应,具有较高的发病率和死亡率。ω-3 多不饱和脂肪酸(ω-3 PUFAs)具有生物学活性。
目的
本研究旨在探讨 ω-3 PUFAs 对抗脓毒症引起的多器官衰竭的信号通路。
材料和方法
采用盲肠结扎穿孔(CLP)法建立脓毒症 Sprague-Dawley(SD)大鼠模型。将大鼠分为对照组、假手术组、模型组、ω-3 PUFAs(0.5g/kg)治疗组、ω-3 PUFAs(0.5g/kg)+AMPK 抑制剂 Compound C(30mg/kg)治疗组和 ω-3 PUFAs(0.5g/kg)+mTOR 激活剂 MHY1485(10mg/kg)治疗组。采用 ELISA 法检测血清炎症细胞因子水平。采用全自动生化分析仪检测心肌钙蛋白 I(cTnI)、肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、肌酐(Cr)、尿素氮(BUN)、丙氨酸氨基转移酶(ALT)和天门冬氨酸氨基转移酶(AST)等器官损伤标志物。采用 Western blot 和 qRT-PCR 方法检测肝、肾和心肌组织中 AMPK/mTOR 通路。
结果
CLP 处理增强了大鼠促炎细胞因子和多器官相关标志物的分泌,同时增加了 p-AMPK/AMPK 比值(从 0.47 增加到 0.87),降低了 p-mTOR/mTOR 比值(从 0.33 降低到 0.12)。0.5g/kg ω-3 PUFAs 治疗可部分拮抗 CLP 处理引起的炎症反应和多器官损伤。CLP 诱导的大鼠 AMPK/mTOR 通路被进一步激活。最后,Compound C 和 MHY1485 可以逆转 ω-3 PUFAs 对脓毒症大鼠的治疗作用。
讨论和结论
ω-3 PUFAs 通过激活 AMPK/mTOR 通路改善脓毒症的发展,可作为脓毒症的有效治疗药物。进一步的研究可能会验证其潜在的临床应用。